Agoracom Blog Home

Archive for the ‘Quantum BioPharma Ltd.’ Category

« Older Entries

Quantum BioPharma’s Year of Execution: Clinical Momentum, Platform Progress, and a Stronger Balance Sheet

Posted by Brittany McNabb at 4:19 PM on Monday, August 18th, 2025

Advancing a Novel Approach to Multiple Sclerosis

Quantum BioPharma Ltd. (NASDAQ: QNTM; CSE: QNTM) is advancing therapies for challenging neurological and related conditions with a lead focus on multiple sclerosis (MS). Its flagship program, Lucid-MS (Lucid-21-302), is a patented, non-immunomodulatory compound designed to protect myelin—the insulating sheath around nerve fibers that is damaged in MS. Unlike many approved MS drugs that primarily suppress immune activity, Lucid-MS targets neuroprotection and myelin integrity, a differentiated strategy supported by preclinical data showing prevention of demyelination and reversal of paralysis.

From First-in-Human to Phase 2 Readiness

The program progressed through first-in-human testing with a Phase 1 multiple-ascending-dose (MAD) trial in healthy adults. The Clinical Study Report (CSR) concluded no safety or tolerability concerns following consecutive daily dosing—an essential milestone for opening the path to patient studies. In parallel, Quantum has signed an agreement with a leading CDMO to manufacture an oral formulation of Lucid-MS as the drug product for its planned Phase 2 clinical trial. The company has also begun preparing key components for an FDA Investigational New Drug (IND) application and submitted Lucid-MS to the UK’s ILAP Passport program, a pathway intended to accelerate access to promising medicines.

Measuring What Matters: Imaging Collaboration with MGH

A frequent obstacle in neuroprotective drug development is proving biological effect. To address this, Quantum is collaborating with Massachusetts General Hospital (MGH) scientists on imaging approaches to monitor myelin integrity. On August 5, 2025, MGH investigators published data in the European Journal of Nuclear Medicine and Molecular Imaging showing that PET tracer [18F]3F4AP exhibited strong brain-imaging properties and could detect differences across MS lesions not visible on conventional MRI. This tracer—developed at MGH and evaluated in healthy controls and people with MS—may serve as a biomarker to track demyelination and treatment response, potentially enhancing the precision of future Lucid-MS efficacy studies.

Pipeline Breadth: Phase 2 Ethics Approval for FSD202 in Australia

Beyond MS, Quantum’s pipeline includes FSD202, which targets nociplastic pain associated with idiopathic Mast Cell Activation Syndrome (MCAS)—a difficult-to-treat presentation of chronic, widespread musculoskeletal pain. In 2025, the company received Human Ethics Review Committee (HERC) approval in Australia for a Phase 2 randomized, double-blind, placebo-controlled trial designed to evaluate safety and efficacy in this population.

Spinout Progress Without Shareholder Dilution

Quantum also created value by spinning out the consumer OTC version of its alcohol-related wellness asset unbuzzd™ to Unbuzzd Wellness Inc. Quantum retains an equity stake (approximately 20% as of mid-2025) and royalty rights of 7% of sales until $250 million is reached, then 3% in perpetuity. In 2025, Unbuzzd launched a Reg D 506(c) capital raise of up to US$5 million to fund growth and a potential go-public path. The company noted this financing does not dilute Quantum BioPharma shareholders. Unbuzzd’s U.S. commercialization continues, with additional regulatory steps underway for Canada.

Strengthening the Balance Sheet

Operational progress has been matched by financial housekeeping. For the quarter ended June 30, 2025, Quantum reported:

  • Current assets of US$10.3 million (up from US$9.9 million at March 31, 2025) and total assets of US$15.3 million (up from US$14.9 million).
  • All debentures converted to equity, removing that liability; previously recorded warrant liability (a non-cash item) was eliminated as all outstanding warrants were exercised by the date of filing.
  • Receipt of a US$2.35 million settlement related to prior management litigation; the Sports Coat litigation loan was fully repaid with full release received.
  • Treasury diversification that includes approximately US$5.5 million of Bitcoin and other cryptocurrencies, with over US$500,000 in realized and unrealized gains as of filing.
  • Management indicated sufficient cash on hand to maintain basic operations beyond March 2027.

During Q2 2025, the share price rose from US$7.71 (March 31) to US$20.25 (June 30), reflecting a period of notable execution across clinical, operational, and financial fronts.

Outlook

Quantum BioPharma enters the next phase with a de-risked safety profile for its lead MS candidate, manufacturing in place for an oral Phase 2 program, and an imaging collaboration that could sharpen efficacy readouts. The company is also advancing FSD202 into a Phase 2 study in Australia and maintaining non-dilutive exposure to a commercializing consumer asset via Unbuzzd. Combined with a cleaner balance sheet and extended cash runway, the setup positions Quantum to pursue upcoming clinical and corporate milestones with focus and flexibility.

All program descriptions reflect company disclosures, published study findings from MGH collaborators, and the most recent financial updates provided by Quantum BioPharma in 2025.

 

Visit $QNTM HUB On AGORACOM : https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

DISCLAIMER AND DISCLOSURE 

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000. 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

Tags: , , ,
Posted in Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma’s Year of Execution: Clinical Momentum, Platform Progress, and a Stronger Balance Sheet

Quantum BioPharma Confronts Extreme Short Pressure Amid Market Imbalances as Borrow Fees Surge Beyond 437%

Posted by Brittany McNabb at 9:55 AM on Friday, June 27th, 2025

Quantum BioPharma (NASDAQ: QNTM / CSE: QNTM) is now facing one of the most severe short pressure environments observed in North American markets this year. The borrow fee on QNTM shares has surged past 437% annually — roughly 1% per trading day — placing it among the highest-cost securities to short across any exchange. These fees signal that brokers are effectively out of lendable inventory and are pricing risk accordingly.

Float Scarcity Driving Volatility Risk

With fewer than 15,000 shares available for borrowing across major prime brokers, QNTM has entered what many refer to as a “locate vacuum.” The company’s public float is approximately 2.6 million shares, making it highly sensitive to buying pressure. In micro-float environments, even small bursts of covering or long-side accumulation can cause rapid price escalation due to a lack of natural sellers and tight liquidity conditions.

Dark Pool Activity Clouds Price Discovery

Adding to concerns is the high proportion of off-exchange short trading. In recent sessions, approximately 59% of QNTM’s daily volume has been routed through dark pools — private trading venues that do not display pre-trade quotes. While such routing is legal, this level of activity can obscure real demand and suppress visible momentum. In an environment where supply is tight and borrow costs are surging, dark pool dominance raises legitimate questions about whether price discovery is functioning as it should.

Echoes of Past Short-Driven Dislocations

The structural setup now surrounding QNTM bears striking similarities to prior market events that resulted in high-profile short squeezes. KaloBios (KBIO) gained over 10,000% in 2015 after its float was effectively locked and borrow availability vanished. GameStop (GME) surged 2,740% in early 2021 under conditions of high borrow fees, float constraints, and elevated short interest. Other comparables include Tilray (TLRY) and KOSS, where borrow fees exceeded 800% during moments of extreme float compression. QNTM’s current borrow rate already exceeds GME’s peak — despite having a much smaller float.

Company Fundamentals Remain Unchanged

While trading volatility has increased, Quantum BioPharma’s operational strategy and clinical programs remain firmly on track. The company recently completed Phase 1 trials for Lucid-MS, a novel treatment designed to repair myelin damage in multiple sclerosis patients. Developed in collaboration with scientists from a Harvard-affiliated teaching hospital, Lucid-MS offers a differentiated approach in a space long dominated by immune suppression therapies. Importantly, the company has made no promotional claims, has not issued new financings, and is not engaged in any stock-related marketing activity.

No Squeeze Assumptions — But Structural Tension Is Clear

A short squeeze is never guaranteed, even with elevated borrow fees and float scarcity. However, the structural tension in QNTM’s trading — characterized by near-zero share availability, high-cost borrow, and dark pool suppression — creates the potential for sudden dislocation if a trigger appears. Any combination of positive news, reduced volume, or insider accumulation could prompt a reflexive covering event in a market ill-equipped to absorb it.

Reaffirming the Need for Market Integrity

Quantum BioPharma has not commented on recent trading behavior but reaffirms its commitment to transparency, scientific advancement, and regulatory compliance. The company supports fair, orderly markets and believes that all participants — including regulators and exchanges — should remain vigilant when structural indicators point to breakdowns in natural price formation. As this situation evolves, investors, analysts, and oversight bodies are encouraged to monitor borrow fees, share availability, and trade routing closely.

Tags: , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, All Recent Posts, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma Confronts Extreme Short Pressure Amid Market Imbalances as Borrow Fees Surge Beyond 437%

Quantum BioPharma’s $700 Million Lawsuit Highlights Ongoing Concerns Over Market Manipulation

Posted by Brittany McNabb at 3:38 PM on Thursday, May 15th, 2025

The biopharmaceutical company’s legal action against major financial institutions underscores the persistent issue of spoofing in financial markets.

Introduction

Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company focused on developing treatments for neurodegenerative disorders, has filed a lawsuit seeking over $700 million in damages. The legal action alleges that CIBC World Markets and RBC Dominion Securities engaged in market manipulation practices, specifically spoofing, which artificially depressed Quantum’s stock price between January 2020 and August 2024. 

Understanding Spoofing and Its Impact

Spoofing is a deceptive trading practice where traders place large orders with the intent to cancel them before execution, creating a false impression of demand or supply. This manipulates market prices and can mislead other investors. The practice was outlawed under the Dodd-Frank Act in 2010 due to its potential to disrupt market integrity.

In Quantum’s case, the company alleges that such spoofing tactics led to a significant decline in its stock value, which was trading above $460 per share in January 2020. The purported manipulation not only affected the company’s market capitalization but also potentially harmed investors who relied on transparent market operations. 

Legal Proceedings and Representation

Quantum BioPharma has engaged the law firms Christian Attar and Freedman Normand Friedland LLP to represent its case on a contingency basis. This arrangement indicates the legal teams’ confidence in the merits of the case and ensures that Quantum can pursue the lawsuit without immediate financial burden. 

The lawsuit, filed in the U.S. District Court for the Southern District of New York, accuses the defendants of violating multiple sections of the Securities Exchange Act. Quantum has also invited shareholders who believe they were affected by the alleged spoofing to share their experiences, aiming to document the broader impact on investor confidence and market fairness. 

Advancements in Multiple Sclerosis Treatment

Amidst the legal battle, Quantum continues to advance its clinical programs. The company’s lead compound, Lucid-MS, is a first-in-class, non-immunomodulatory, neuroprotective treatment for multiple sclerosis (MS). Unlike traditional MS therapies that suppress the immune system, Lucid-MS aims to protect and restore the myelin sheath surrounding nerve fibers, addressing the root cause of the disease. 

In February 2025, Quantum announced the completion of its Phase 1 clinical trial for Lucid-MS, reporting that the treatment was well-tolerated with no serious adverse events. The company is now preparing to initiate Phase 2 trials, bringing it closer to offering a novel therapeutic option for MS patients.

Conclusion

Quantum BioPharma’s lawsuit against major financial institutions brings to light the ongoing challenges of ensuring market integrity in the face of sophisticated trading manipulations like spoofing. As the company seeks justice through legal channels, it remains committed to its mission of developing innovative treatments for debilitating diseases, exemplified by the progress of Lucid-MS.

Investors and industry observers will be closely monitoring the outcomes of both the legal proceedings and the clinical advancements, as they hold significant implications for market practices and medical breakthroughs alike.

Source: https://corporatefinanceinstitute.com/resources/career-map/sell-side/capital-markets/spoofing/

Visit $QNTM HUB On AGORACOM : https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

DISCLAIMER AND DISCLOSURE 

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000. 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

Tags: , , , , ,
Posted in AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, All Recent Posts, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma’s $700 Million Lawsuit Highlights Ongoing Concerns Over Market Manipulation

Quantum BioPharma’s Lucid-MS Offers New Hope For Multiple Sclerosis Treatment

Posted by Brittany McNabb at 2:21 PM on Tuesday, April 22nd, 2025

Revolutionizing MS Care: A New Approach Emerges

Multiple sclerosis (MS) affects about 2.8 million people worldwide, causing symptoms like tiredness, difficulty moving, and memory problems. Traditional treatments mainly focus on controlling the immune system to reduce inflammation, but they don’t always address the damage done to the protective covering around nerve fibers, which leads to ongoing disability.

Quantum BioPharma, a company focused on new treatments for brain and nerve diseases, is taking a different approach with Lucid-MS. This new compound aims to protect and even repair the nerve fiber covering, offering a fresh approach to treating MS.

Lucid-MS: A New Treatment Option

Lucid-MS is a patented compound designed to stop and even reverse the damage to the nerve fiber covering, which is a key factor in MS. Unlike current treatments that focus on controlling the immune system, Lucid-MS works to protect and restore the nerve covering without affecting the immune system.

Clinical Milestone: Phase 1 Trial Completed

In February 2025, Quantum BioPharma announced that it successfully completed the first phase of testing Lucid-MS in healthy adults. The trial tested the safety and how the body processes the compound. The results showed no serious side effects, and Lucid-MS was well-tolerated by all participants.

Dr. Andrzej Chruscinski, Vice President of Scientific and Clinical Affairs at Quantum BioPharma, said, “We’re excited that this Phase 1 trial is complete and that Lucid-MS was found to be safe and well-tolerated. This is an important step forward and sets the stage for the next phase of development.”

Moving to Phase 2: Targeting MS Patients

Now that Phase 1 is complete, Quantum BioPharma is getting ready to start Phase 2 trials to test Lucid-MS in people with MS. This phase will focus on seeing if Lucid-MS can slow or stop the damage to the nerve covering in people with MS.

CEO Zeeshan Saeed shared his excitement: “We’re very hopeful that Lucid-MS can protect the nerve covering in MS patients, which represents a new approach to treating the disease. With Phase 1 complete and the safety confirmed, we’re now ready to move on to testing it in MS patients.”

Working Together: Improving MS Diagnosis

Along with developing Lucid-MS, Quantum BioPharma is working with scientists at Massachusetts General Hospital to test a new imaging technique. This advanced scan will help doctors see the condition of the nerve covering in MS patients, giving a better way to track the disease and see how well treatments are working.

Conclusion: A Bright Future for MS Treatment

Quantum BioPharma’s work with Lucid-MS could change the way MS is treated by focusing on protecting and repairing nerve fibers, rather than just controlling the immune system. As they move forward with Phase 2 trials, both doctors and patients are eagerly awaiting what comes next.

For more information on Quantum BioPharma and Lucid-MS, please visit www.quantumbiopharma.com.

Source: https://www.ninds.nih.gov/health-information/disorders/multiple-sclerosis

YOUR NEXT STEPS 

Visit $QNTM HUB On AGORACOM: https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

Watch $QNTM Videos On AGORACOM YouTube Channel:

https://studio.youtube.com/playlist/PLfL457LW0vdK6S1r-_VHqbuWQNDV4fV-D/videos

DISCLAIMER AND DISCLOSURE 

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000. 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

Tags: , , , ,
Posted in AGORACOM Client Feature, AGORACOM Small Cap Stocks For Investment, AGORACOM Traffic, All Recent Posts, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma’s Lucid-MS Offers New Hope For Multiple Sclerosis Treatment

Quantum BioPharma’s Secret Weapon: A Dual Engine of Clinical Innovation and Consumer Expansion

Posted by Brittany McNabb at 11:10 AM on Wednesday, April 16th, 2025

From clinical breakthroughs in multiple sclerosis to a fast-growing alcohol detox brand, Quantum BioPharma is bridging biotech innovation with real-world impact.

A Biopharma Platform Tackling Today’s Toughest Health Challenges

Quantum BioPharma Ltd. (NASDAQ: QNTM | CSE: QNTM) is emerging as a dynamic force in the biotechnology sector, developing solutions for two major public health issues: neurodegenerative diseases and alcohol misuse. With a diversified pipeline spanning prescription drugs and over-the-counter consumer products, the company is building an integrated portfolio capable of delivering both near-term commercial gains and long-term medical breakthroughs.

The company’s strategy is uniquely positioned at the intersection of science, innovation, and unmet need — making it one of the few small-cap biotechs advancing both FDA-bound therapeutics and consumer-ready wellness products simultaneously.

Lucid-MS: Targeting the Root Cause of Multiple Sclerosis

At the heart of Quantum’s pharmaceutical program is Lucid-MS, a patented new chemical entity showing early promise in treating multiple sclerosis (MS). Unlike conventional MS drugs that focus on managing inflammation, Lucid-MS addresses the core driver of long-term disability in MS: the breakdown of the myelin sheath — the protective layer around nerve fibers.

Following a successful Phase 1 clinical trial, the drug has been deemed safe and well-tolerated, with therapeutic blood levels observed in healthy participants. Quantum is now preparing to launch a Phase 2 trial in 2026, targeting efficacy in MS patients.

What makes Lucid-MS even more distinctive is Quantum’s collaborative study with Massachusetts General Hospital (MGH), featuring scientists from Harvard Medical School, to validate advanced PET imaging as a way to monitor demyelination in real time. This partnership elevates both the scientific credibility and clinical precision behind Lucid-MS, positioning it as a next-generation therapeutic candidate in a $27 billion global MS treatment market.

unbuzzd™: A Consumer Wellness Product with Scientific Backing

In parallel with its clinical pipeline, Quantum BioPharma is making significant inroads in the consumer wellness market through unbuzzd™, an over-the-counter alcohol detox and recovery beverage developed by its spinout, Celly Nutrition Corp. The product, a fast-acting powder stick formulated by pharmacology experts, is designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms.

unbuzzd™ is already making retail waves. Backed by a double-blind, placebo-controlled clinical trial, the beverage demonstrated that it could reduce blood alcohol concentration (BAC) over 40% faster than placebo in many subjects. It’s now available via Amazon and unbuzzd.com, with retail expansion underway in the U.S., Puerto Rico, and the Caribbean through a new distribution agreement with FUSION Distribution Group.

Most recently, unbuzzd™ entered a landmark partnership with AATAC, one of the largest retail networks in the U.S., which connects the product to over 80,000 convenience store locations. This expansion gives unbuzzd™ exposure to leading chains like 7-Eleven, Circle K, Shell, and ampm — significantly scaling its retail footprint.

Multiple Value Streams, One Vision

Quantum BioPharma holds 25.71% ownership in Celly Nutrition and receives up to 7% in royalties from unbuzzd™ sales until a $250M threshold is met — and 3% in perpetuity thereafter. This structure offers upside exposure to the high-growth consumer market while maintaining strategic focus on the pharmaceutical pipeline.

With an improved cash position, enhanced operational efficiency, and momentum across both drug development and consumer wellness fronts, the company is now advancing toward key inflection points on multiple fronts.

A Biotech Story Worth Watching

With a first-in-class MS treatment advancing toward Phase 2 trials, a consumer product already on shelves and gaining market traction, and elite partnerships with global institutions like Harvard and AATAC — Quantum BioPharma stands apart in the small-cap biotech landscape.

It’s not just a company developing drugs. It’s building a platform for impact, backed by scientific validation and commercial momentum.


YOUR NEXT STEPS 

Visit $QNTM HUB On AGORACOM: https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

Watch $QNTM Videos On AGORACOM YouTube Channel:

https://studio.youtube.com/playlist/PLfL457LW0vdK6S1r-_VHqbuWQNDV4fV-D/videos

DISCLAIMER AND DISCLOSURE 

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000. 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

Tags: , , , , , , , ,
Posted in Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma’s Secret Weapon: A Dual Engine of Clinical Innovation and Consumer Expansion

Canadian Biotech Quantum BioPharma Nears a Landmark Multiple Sclerosis Breakthrough

Posted by Brittany McNabb at 9:54 AM on Thursday, March 27th, 2025

New Approach Could Redefine How Multiple Sclerosis Is Treated Worldwide

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) may be on the verge of redefining treatment for multiple sclerosis (MS), a chronic neurological disorder affecting nearly 3 million people worldwide. In a compelling interview on the AGORACOM, Dr. Andrzej Chruscinski, Vice-President of Scientific and Clinical Affairs at Quantum BioPharma, detailed the company’s successful completion of its Phase 1 clinical trial for Lucid-MS, a first-in-class neuroprotective drug targeting demyelination—the core driver of MS progression.

Unlike existing treatments, which primarily focus on managing the immune system and controlling inflammation, Lucid-MS takes aim at protecting and potentially repairing the myelin sheath—the protective layer around nerve cells that degenerates in MS patients. “We’re excited about the potential of Lucid-MS to protect myelin in MS patients as it represents a new direction in the treatment of this disease,” said Quantum BioPharma CEO Zeeshan Saeed.

A Novel Solution to a Persistent Problem

Most MS therapies today only address the inflammatory aspect of the disease, leaving the underlying neurodegeneration largely unaddressed. Lucid-MS changes that narrative.

  • The drug works by preventing the unraveling of the myelin sheath, a process triggered by a chemical modification known as citrullination.

  • Developed over a decade by Dr. Lakshmi Kotra and Dr. Mario Moscarello at the University of Toronto, Lucid-MS targets this key process, aiming to halt disease progression and protect nerve communication.

  • The approach has already shown success in preclinical animal models.

“Think of the myelin sheath like insulation around electrical wiring. When that’s compromised, signals can’t transmit properly,” explained Dr. Chruscinski. “Our drug preserves that insulation, maintaining neural function.”

Phase 1 Trial: Safety Confirmed, Therapeutic Potential Emerges

The recently completed Phase 1 trial focused on evaluating safety and pharmacokinetics in healthy participants. According to Dr. Chruscinski, “Lucid-MS was safe and well-tolerated, with no adverse events. We’re also pleased with the drug levels observed in blood, which we believe are therapeutic.”

This milestone is crucial for advancing to Phase 2, where the company will begin testing Lucid-MS in MS patients to assess efficacy.

What to Expect in Phase 2

The company is actively designing its Phase 2 trial with a projected start in Q1 2026, pending FDA clearance via an Investigational New Drug (IND) application in late 2025.

Key details under consideration:

  • The trial will include roughly 60 MS patients (30 receiving Lucid-MS and 30 on placebo).

  • Outcomes will be measured using MRI scans and clinical assessments to evaluate both biological and functional improvement.

  • While the exact location is yet to be confirmed, Quantum is exploring options to include Canadian sites in recognition of the drug’s Canadian origins.

Support From the Scientific Community

Feedback from global experts at major MS conferences in North America and Europe has been overwhelmingly positive. “The response has been tremendous,” said Dr. Chruscinski. “There’s a real appetite for a drug that targets neurodegeneration, which remains an unmet need in MS.”

This third-party validation underscores the broader scientific and commercial relevance of Quantum BioPharma’s work.

A Human-Centered Mission With Investor Appeal

Dr. Chruscinski also emphasized his personal motivation. “It’s exciting to be part of something that could make a real difference. I was there when the first dose was administered in our Phase 1 trial. That’s a moment I won’t forget.”

While the drug development process remains long and complex, Quantum BioPharma has achieved a significant milestone that positions the company—and Lucid-MS—at the forefront of innovation in MS treatment.

For investors, the opportunity lies in Quantum’s unique approach, successful early data, and a clearly defined path toward a potential market-shifting solution.

Conclusion: A Meaningful Milestone With a Promising Horizon

With a Phase 1 trial successfully completed and a novel therapeutic mechanism unlike anything currently on the market, Quantum BioPharma is emerging as a company to watch in the fight against multiple sclerosis. As it gears up for its Phase 2 trial and FDA engagement, the company stands at a pivotal inflection point—one that could not only deliver long-term value for investors but also reshape the future of MS care.

To hear Dr. Chruscinski explain the science, milestones, and next steps in his own words, watch the full interview here: 

Tags: , , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, AGORACOM Via Satellite, All Recent Posts, Quantum BioPharma Ltd. | Comments Off on Canadian Biotech Quantum BioPharma Nears a Landmark Multiple Sclerosis Breakthrough

Canadian Small Cap Quantum BioPharma on The Verge of Multiple Sclerosis Breakthrough

Posted by Brittany McNabb at 5:01 PM on Tuesday, March 25th, 2025

KEY MILESTONES AND WHAT’S NEXT

  • Successful Phase 1 Trial: Lucid-MS has shown excellent safety with no serious side effects, paving the way for a groundbreaking treatment for MS.
  • Next Major Step: The Phase 2 trial is set for early 2026, with 60 participants.
  • FDA Submission on the Horizon: Plans to submit application to the FDA by late 2025, taking a huge step toward regulatory approval.
  • Massive Market Opportunity: With 2.9 million people worldwide affected by Multiple Sclerosis and the market projected to surpass $30 billion by 2030, Lucid-MS could potentially capture a significant share of this rapidly expanding space.

A NEW ERA IN MULTIPLE SCLEROSIS TREATMENT

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Lucid-MS is setting the stage to revolutionize MS treatment. Unlike existing therapies that only target immune system responses, Lucid-MS focuses on protecting and repairing myelin, the critical layer around nerve fibers. This novel approach has the potential to slow or even reverse disease progression—offering new hope for millions of MS sufferers.

HOW DOES IT WORK? A TOTALLY NEW APPROACH TO TREATING MS

Think of nerves like electrical wires in your body, and myelin as the protective coating around those wires. With Multiple Sclerosis, the immune system attacks this coating (called demyelination), causing damage that leads to muscle weakness, vision problems, and difficulty moving.

Most MS treatments try to calm the immune system to slow down the attack. Lucid-MS is different. Instead of focusing on the immune system, it works directly on the myelin to stabilize and protect it from damage.

WHY IS THIS IMPORTANT?

By keeping myelin intact, Lucid-MS may help slow down the progression of MS and prevent disability—something current MS drugs don’t do very well.

SCIENTIFIC BREAKTHROUGH BACKED BY INDUSTRY RECOGNITION

Lucid-MS is backed by cutting-edge research from Dr. Lakshmi Khotra’s lab at the University of Toronto, where the critical process of myelin breakdown in MS patients was discovered. The drug’s ability to address this underlying issue is a potential game-changer in neurodegenerative treatments.

It’s already gaining enthusiastic support from leading medical experts and researchers, underscoring its transformative potential.

A VISION FOR THE FUTURE

Dr. Andrzej Chruscinski, Vice President of Scientific and Clinical Affairs at Quantum BioPharma, expressed the company’s excitement about Lucid-MS’s future.

“We are on the cusp of something monumental. Lucid-MS has the potential to transform MS treatment and open doors for treating other nerve-related diseases. As we move toward Phase 2 and beyond, we’re excited to bring this innovative therapy to the patients who need it most.”

With promising clinical results, a massive market opportunity, and rising industry recognition, Quantum BioPharma is leading the charge in next-generation treatments for Multiple Sclerosis 

YOUR NEXT $QNTM STEPS

$QNTM HUB On AGORACOM: https://agoracom.com/ir/Quantumbiopharma $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopha… $QNTM Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/Quantumbiopha… Connect With AGORACOM Anyway You Like AGORACOM Website: https://www.agoracom.com – The Most Trusted Source Of Small Cap Information AGORACOM YouTube: Hit That Subscribe Button Right Now For More Powerful Videos AGORACOM X: https://www.x.com/AGORACOM Verified Top 0.2% Account AGORACOM Spotify: https://open.spotify.com/show/74mVPkf… Planes, Trains, Automobiles & Walking The Dog AGORACOM

Tags: , , , , ,
Posted in AGORACOM Via Satellite, Quantum BioPharma Ltd. | Comments Off on Canadian Small Cap Quantum BioPharma on The Verge of Multiple Sclerosis Breakthrough

Quantum BioPharma Successfully Completes First Human Trial for New Multiple Sclerosis Drug 

Posted by Brittany McNabb at 1:18 PM on Monday, March 24th, 2025

Key Takeaway for Investors:
Quantum BioPharma (NASDAQ: QNTM) has successfully completed its Phase 1 clinical trial for Lucid-21-302 (Lucid-MS), an experimental drug for multiple sclerosis (MS). The drug was found to be safe and well-tolerated, paving the way for the next phase of clinical testing.

What Happened?
The company conducted a Phase 1 trial to test the safety of Lucid-MS in healthy volunteers. The study followed strict protocols, including a final review by a Safety Review Committee, which confirmed there were no safety concerns or serious side effects.

Why This Matters:
Lucid-MS is a first-of-its-kind drug designed to protect the myelin sheath around nerve fibers, which is damaged in MS patients. Unlike existing MS treatments, which primarily focus on the immune system, Lucid-MS directly works to stabilize myelin, potentially slowing disease progression.

Next Steps:
With safety confirmed, Quantum BioPharma now plans to move forward with a Phase 2 trial, which will test Lucid-MS in MS patients to evaluate its effectiveness in treating the disease.

CEO Statement:
Zeeshan Saeed, CEO of Quantum BioPharma, emphasized the significance of this milestone, stating that the company is now closer to making a breakthrough treatment for MS patients a reality.

Investor Outlook:
The successful completion of Phase 1 is a major step toward potential drug approval and commercialization. Investors should keep an eye on upcoming Phase 2 trial developments, as positive results could significantly increase the drug’s market potential.

What Does Lucid-21-302 Do? (In Simple Terms)

Lucid-21-302 (Lucid-MS) is a new experimental drug designed to protect nerve fibers in people with multiple sclerosis (MS).

How Does It Work?
Think of nerves like electrical wires in your body, and myelin as the protective coating around those wires. In MS, the immune system attacks this coating (called demyelination), causing damage that leads to muscle weakness, vision problems, and difficulty moving.

Most MS treatments try to calm the immune system to slow down the attack. Lucid-MS is different. Instead of focusing on the immune system, it works directly on the myelin to stabilize and protect it from damage.

Why Is This Important?
By keeping myelin intact, Lucid-MS may help slow down the progression of MS and prevent disability—something current MS drugs don’t do very well.
If future trials confirm its effectiveness, it could be a game-changer for people living with MS.

Source: https://agoracom.com/ir/Quantumbiopharma/forums/discussion/topics/808536-Quantum-BioPharma-Advances-Multiple-Sclerosis-Drug-with-Successful-Phase-1-Trial-Completion-A-Milestone-in-MS-Treatment-Development/messages/2432086

 

Tags: , , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma Successfully Completes First Human Trial for New Multiple Sclerosis Drug 

Quantum BioPharma Targets $40B MS Market with Lucid-MS Following Successful Phase 1 Trial – Poised for $1B+ Potential

Posted by Brittany McNabb at 4:32 PM on Thursday, February 27th, 2025

Industry Outlook and Quantum BioPharma’s Trajectory

The multiple sclerosis (MS) treatment market is undergoing a transformation. With increasing research into neuroprotection and remyelination, the industry is shifting beyond traditional immune-modulating therapies. The global MS drug market, expected to surpass $40 billion by 2030, is being driven by demand for innovative treatments that go beyond symptom management.

Quantum BioPharma Ltd. (NASDAQ: QNTM) is emerging as a key player in this landscape with its lead drug candidate, Lucid-21-302 (Lucid-MS). The successful completion of its Phase 1 multiple ascending dose clinical trial represents a significant step toward offering MS patients a potential first-in-class neuroprotective treatment. The trial results confirmed no safety concerns and set the stage for Phase 2 trials in MS patients, positioning Quantum BioPharma as an industry leader in advancing non-immunomodulatory solutions.

Voices of Authority

Scientific leaders continue to emphasize the need for alternative MS treatments that address demyelination, rather than focusing solely on immune suppression. Quantum BioPharma’s Vice-President of Scientific and Clinical Affairs, Dr. Andrzej Chruscinski, reinforced the importance of Lucid-MS in meeting this demand:

“We are thrilled that Lucid-MS was deemed safe and well-tolerated in healthy participants. This marks an important milestone and allows for the next steps in the clinical development of Lucid-MS.”

Quantum BioPharma’s CEO, Zeeshan Saeed, highlighted the company’s broader vision:

“By completing this trial and demonstrating safety in healthy participants, we are now closer to initiating a Phase 2 trial of Lucid-MS in people with MS. We look forward to executing our milestones, driven by our mission to arrest demyelination in MS.”

Quantum BioPharma’s FLASH Highlights

Quantum BioPharma has strategically positioned itself at the forefront of neurodegenerative and metabolic disorder treatment development, with a pipeline designed to address high-value, underserved markets. Key achievements include:

  • Lucid-MS Progression: Completion of a successful Phase 1 trial, clearing a major regulatory hurdle and setting up Phase 2 studies.
  • Unbuzzd™ Market Expansion: Quantum BioPharma holds a 25.71% equity stake in Celly Nutrition Corp., licensing its breakthrough alcohol detox beverage, unbuzzd™, with royalty payments contributing to sustained revenue streams.
  • Innovative Growth Strategy: The company continues to diversify its treasury, with forward-thinking financing strategies including cryptocurrency investments and dual listings on Upstream, expanding global investor accessibility.

Real-world Relevance

For MS patients, treatment breakthroughs can mean the difference between maintaining mobility and facing long-term disability. Lucid-MS aims to fill a critical treatment gap by focusing on stabilizing and protecting the myelin sheath, addressing the core issue of MS progression rather than just reducing flare-ups.

Similarly, unbuzzd™ is tackling a widely recognized consumer need—accelerating alcohol metabolism while promoting recovery. With growing attention on functional beverages and wellness products, the supplement represents an additional revenue channel backed by scientifically validated results.

Looking Ahead with Quantum BioPharma

With Lucid-MS advancing to Phase 2 trials and continued market expansion of unbuzzd™, Quantum BioPharma remains well-positioned for long-term growth and industry leadership. The company’s dual focus on biotech innovation and strategic investment diversification sets it apart as a high-potential opportunity for investors seeking exposure to both pharmaceutical breakthroughs and high-growth consumer health markets.

Conclusion

Quantum BioPharma is aligning itself with the industry’s shift toward next-generation MS treatments and functional wellness solutions. The successful completion of its Phase 1 trial for Lucid-MS, combined with its diversified portfolio and strategic financial initiatives, reinforces its role as a compelling player in biotech and healthcare innovation. As the company moves forward with its Phase 2 trial and market expansion plans, investors will be watching closely for its next milestones.

Source: https://agoracom.com/ir/Quantumbiopharma/forums/discussion/topics/808536-Quantum-BioPharma-Advances-Multiple-Sclerosis-Drug-with-Successful-Phase-1-Trial-Completion-A-Milestone-in-MS-Treatment-Development/messages/2432086

 

Tags: , , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, All Recent Posts, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma Targets $40B MS Market with Lucid-MS Following Successful Phase 1 Trial – Poised for $1B+ Potential

Quantum BioPharma (Formerly FSD Pharma) Sues CIBC, RBC & Others For $700 Million Alleging Spoofing/Short Selling Stock Manipulation

Posted by Brittany McNabb at 5:21 PM on Tuesday, November 19th, 2024

In a bold move to safeguard its interests and fight back against market manipulation, Quantum BioPharma (Formerly FSD Pharma)has filed a $700 million lawsuit against CIBC, RBC & Others. The lawsuit alleges that the banks engaged in the controversial practice of “spoofing,” which involves manipulating stock prices by placing fake buy and sell orders to create a false illusion of market demand or supply. According to Quantum BioPharma, this tactic has been used to artificially depress its stock price, potentially causing substantial harm to its investors and undermining the company’s growth prospects.

The Allegations: A Market Manipulation Scheme

Zeeshan Saeed, CEO of Quantum BioPharma, discussed the shock of discovering that the company’s stock had been targeted by a manipulation scheme. He explained that spoofing, a practice where orders are placed and canceled in fractions of a second, can have a profound impact on market prices. These orders are meant to deceive other investors into believing that there is either a shortage of supply or an excess of demand, thus influencing market behavior without any intention to execute the orders. While the practice can be difficult to track due to the speed and subtlety of the actions involved, its effects on stock prices can be devastating.

The suit alleges that CIBC, RBC & others used this technique to artificially suppress Quantum BioPharma’s stock price, potentially wiping out substantial investor value. The company claims that this market manipulation has not only impacted its share price but has also hindered its ability to raise capital, secure financing, and pursue its growth strategies.

A Systemic Issue Impacting Micro-Cap Companies

The conversation extended to the broader implications of stock manipulation, particularly for micro-cap and nano-cap companies that are especially vulnerable to such tactics. Jason Sawyer, Head of Finance and M&A, pointed out that small companies with lower market capitalization and liquidity are often the targets of these manipulations. These tactics are detrimental not only to individual companies but to the entire market ecosystem, particularly in Canada’s venture capital sector. Sawyer emphasized that the loss of trust in the integrity of financial markets—especially within the micro-cap space—has had far-reaching consequences, making it increasingly difficult for companies like Quantum BioPharma to attract investment.

Both Saeed and Sawyer underscored that this lawsuit is not only important for Quantum BioPharma but for many other companies in the sector that may have been victims of similar manipulation. The legal action seeks to address a systemic issue that has been undermining the growth of innovative companies and damaging the confidence of retail investors.

A Legal Strategy with Significant Implications

Quantum BioPharma’s lawsuit, filed in the Southern District of New York, is a strategic step to ensure that the company’s interests are protected and that justice is served. The Southern District is renowned for its experience in handling complex financial cases, making it a favorable jurisdiction for cases of this nature.

The law firm representing Quantum BioPharma is taking the case on a contingency basis, signaling confidence in the strength of the lawsuit. This mirrors past successful cases, such as Erin Brockovich’s legal efforts, and suggests that the firm believes the case has merit without requiring upfront payment. Shareholders of Quantum BioPharma have expressed strong support for the lawsuit, recognizing its potential to restore fairness and the natural order to supply and demand in the company’s market activity, while compensating the company for the immense damage caused.

Additionally, the company is providing a platform for investors who believe they have been harmed by the alleged manipulation, offering them the opportunity to join the legal action and submit claims. This has fostered a sense of unity among shareholders and further strengthens the company’s resolve in its legal battle.

Potential Industry-Wide Impact

This lawsuit has the potential to set a significant precedent for other companies affected by similar forms of market manipulation. Quantum BioPharma has already received inquiries from other firms seeking guidance on how to pursue similar legal actions, highlighting the broader relevance of the case.

While the lawsuit is expected to take time, with motions to dismiss likely to be filed by the banks, the company remains focused on its core business activities. The litigation is seen as a crucial step in protecting the company’s long-term interests and ensuring that its shareholders are treated fairly in the marketplace. Discovery, the phase in which both parties exchange evidence, is expected to begin after motions are resolved, which could take 9 to 15 months.

Commitment to Shareholders and Future Growth

Quantum BioPharma has made it clear that its primary focus remains the ongoing commercialization of its innovative biotech products, including its neuroprotective compound, Lucid-MS. However, the company views the legal action as a secondary but essential part of its strategy to secure a fair and transparent market environment. A successful outcome in the lawsuit could not only recover damages for the company but also provide significant financial support for continued research and development, as well as potential acquisitions.

Furthermore, Quantum BioPharma’s leadership has reaffirmed its commitment to its shareholders. The company’s actions, including the filing of this lawsuit and its ongoing efforts to protect investor value, demonstrate its determination to safeguard the interests of its investors and ensure that the company can continue to thrive despite the challenges it faces.

Conclusion: Fighting for Market Integrity

Quantum BioPharma’s lawsuit is a bold stand against market manipulation and an important step in the broader fight for fairness and transparency in financial markets. By taking legal action against two of Canada’s largest banks, the company is not only seeking justice for itself and its investors but is also sending a message that such manipulative practices will not be tolerated.

As the legal battle unfolds, Quantum BioPharma remains committed to its mission of advancing groundbreaking biotech solutions while ensuring that its shareholders can invest in a company that values integrity, transparency, and accountability. The outcome of this case could have far-reaching implications for the biotech sector, offering a crucial opportunity to restore trust in the venture capital markets and set a positive precedent for other companies facing similar challenges.

Tags: , , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, All Recent Posts, FSD Pharma Inc., Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma (Formerly FSD Pharma) Sues CIBC, RBC & Others For $700 Million Alleging Spoofing/Short Selling Stock Manipulation

« Older Entries